Echo He

Echo He, M.D., Ph.D., is a former senior vice president and senior analyst with the Maxim Group. Prior to joining Maxim, she was a director at Oppenheimer & Co. Inc., where she conducted equity analysis of small- to mid-cap U.S.-listed Chinese stocks. Dr. He also served as a vice president at CRT Capital Group LLC, where she conducted equity and credit analysis of Chinese small-cap, U.S.-based life science and distressed companies. Dr. He was a research scientist at the National Institutes of Health (NIH), where she conducted a part of the Human Genome Project, aimed at interpreting diseases and their risks by genetic patterns. Dr. He received a medical doctorate from Beijing University, a doctorate in medical sciences from the University of Toledo and a master's of business administration in finance and economics from the University of Chicago.
Recent Quotes
"THLD's preliminary multiple myeloma data may lead to an expanded trial."
—
Echo He, Maxim Group
(6/3/14)
more >
"ARNI made significant progress on the clinical development of its lead drug, onapristone.
—
Echo He, Maxim Group
(5/9/14)
more >
"One catalyst for RNN might be a partnership with a big pharma on its two oral compounds in phase 1."
—
The Life Sciences Report Interview with Echo He
(1/30/14)
more >
"CPRX's Firdapse has both orphan drug status and breakthrough designation."
—
The Life Sciences Report Interview with Echo He
(1/30/14)
more >
"ARNI's collaboration with Leica Biosystems serves as a validation to onapristone's scientific foundation and development operations."
—
Echo He, Maxim Group
(1/22/14)
more >
"We believe CPRX's Firdapse clinical program, pathway and commercial plan are both sound and viable."
—
Echo He, Maxim Group
(10/18/13)
more >
"We are initiating coverage of CPRX with a Buy rating."
—
Echo He, Maxim Group
(9/24/13)
more >
"GALE's long term, risk reward profile is favorable."
—
Echo He, Maxim Group
(6/12/13)
more >